- Open Access
Immune microenvironment as a factor of breast cancer progression
© Romaniuk and Lуndіn. 2015
- Received: 25 February 2015
- Accepted: 4 June 2015
- Published: 26 June 2015
The rate of progression of the disease depends on various factors and the tumor microenvironment takes not the last place among them. One part of researchers argues that the presence of tumor-infiltrating leukocytes serves as a favorable marker of the disease. There exists a completely different point of view on the matter.
The investigation of the effects of the inflammatory infiltration on the course of breast cancer process.
We found a pronounced inflammatory infiltration in the tumor microenvironment in 24 cases. Nineteen cases of IDC without inflammatory infiltration were used as a control group. Immunohistochemical reaction showed expression of ERα, PR, HER2/neu, E-cadherin, Hsp90α, Bcl-2, CD3, CD79α, S100 and Myeloperoxidase receptors. Mathematical calculations were done using Microsoft Excel 2010 with 12.0.5 Attestat option.
We have determined five variants of immune microenvironment: interstitial, trabecular, nodular, diffuse and mixed. We have established a direct correlation between the expression of ERα and PR and indirect correlation between the receptors of steroid hormones and HER2/neo in both groups of breast cancer. HER2/neo positive tumors in 100% of cases were accompanied by the presence of heat shock proteins. There was a combination of Bcl-2 presence with the steroid receptors expression in 90 % of cases. There was found the indirect correlation between the presence of B lymphocytes and expression of steroid receptors.
The presence of B lymphocytes in an inflammatory infiltrate leads to the disappearance of estrogen receptors and progesterone receptors. It provokes the accumulation of Hsp90 in a cell. It contributes to the stabilization of HER2/neu receptors and most proteins that promote tumor progression.
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1362330168161694
- Breast cancer
- Inflammatory infiltration
The rate of progression of breast cancer depends on various factors. The histological type of tumor, its reasons, the woman’s age, the hormonal condition, the tumor microenvironment, the status of the receptors and genetic material, etc. were described as the prognostic factors of breast cancer .
There are two different forms of estrogen receptor (ER), usually referred to as α and β, each encoded by a separate gene (ESR1 and ESR2, respectively). ESR1 is localized on the sixth chromosome, and ESR2 - on the fourteenth chromosome . The connection of the hormone (17β-estradiol) with receptors causes dissociation of the complex with receptor protein hsp90, which impedes the transition of the receptor in the active conformational state. Further, as a heterodimer receptor it interacts with the estrogen response element (ERE), increasing the expression of the necessary genes . The gene that encodes the progesterone receptor (PR) is located on the eleventh chromosome. The number of PR increases with the rising amount of estradiol and ER because they are synthesized after ER . In contrast to these favorable prognostic indicators, the presence of human epidermal growth factor receptor 2 (HER2/neu) is a factor of tumor aggression. ERBB2 (coding gene HER2/neu), known as proto-oncogene, is located on a long arm of human seventeenth chromosome [5, 6].
The self-regulation tumorous process and participation of antitumor immunity in it are acute in many scientific studies. From this perspective the tumor microenvironment occupies a key position. One part of researchers argues that the presence of tumor-infiltrating leukocytes serves as a favorable marker of the disease . The studies of the relationship between immune response and prevalence of breast cancer have shown that with the decrease of leukocyte infiltration around the tumor cells the frequency of regional lymph nodes lesion is increased . On the one hand the immune microenvironment restricts prevalence of the tumor, on the other hand manifests its cytotoxic effect against the phenotypic-foreign breast cancer cells. There exists a completely different point of view on the matter . It has been shown that the immune microenvironment determines the proliferative activity of the tumor, metastasis and cell migration. This process is carried out by the ability of cells to perceive signaling molecules such as pro-inflammatory cytokines, selectins, chemokines which are secreted by inflammatory cells as well as secrete them. But as it turned out the prognosis of breast cancer depends more on qualitative composition of the infiltration .
The questions about the influence of the inflammatory response on the expression of the receptors have been discussed in a great deal of studies repeatedly . Nuclear factor (NF-kB) was described as one of the inhibiting factors for ER . It is activated by a variety of stimuli, including cytokines (interleukin 1 - IL-1) and stress factors (such as reactive forms of oxygen). In the presence of IL-1, NF-kB becomes active. It is translocated into the nucleus for activation the transcription of the controlled genes. NF-κB can inhibit ER in different ways activating inhibitors and inhibiting activators of ESR1 and ESR2 transcription [13–15].
One important mechanism of cell survival is the activation of the transcription different anti-apoptotic proteins of the bcl-2 family by NF-kB signaling cascade [16, 17]. One of pro-survival proteins Bcl-2 family bcl-2 inhibits caspases due to the prevention of exiting cytochrome C from mitochondria and/or due to the binding factor APAF1 which activates apoptosis . There is information that transcription of the gene Bcl-2 is activated by the signals received from the ER .
Heat shock protein 90 (hsp90, chaperone 90) is one of regulatory factors which controls activity of HER2/neu receptors . It has been suggested that hsp90 modulates the effects of oncogenic HER2/neu, representing a potential mechanism of breast cancer resistance to HER2/neu directed drugs . They are involved in maintaining the integrity of mitochondrial activating bcl-2, promoting the invasion step of metastasis and regulating the activity of factors Akt, NF-kB and JKN [22, 23]. Many investigations have shown the cross-resistance phenomenon in which some damaging agents (oxidase stress, heavy metal ions, inflammatory process) cause induction of hsp90 synthesis and adaptive response to other factors .
Analyzing the above it can be concluded that the inflammatory cells of the tumor microenvironment are directly involved in cell activity. The mechanism of combined effect immune cells on the expression of vitally important receptor of breast cancer cells remains unclear.
The objectives of this paper are as follows: the investigation of the effects of the inflammatory infiltration on the course of malignant process by determining qualitative composition of tumor microenvironment and studying the expression of the prognostic-important receptors in the breast cancer cells.
We selected 43 samples of breast cancer tissue. The diagnosis of invasive ductal carcinoma (IDC) with varying degrees of malignancy (by Scarff-Bloom-Richardson) was found after the standard hematoxylin eosin staining of prepared slices. We found a pronounced inflammatory infiltration in the tumor microenvironment in 24 cases. Nineteen cases of IDC without inflammatory infiltration were used as a control group.
Antibody for immunohistochemical reaction
Cytoplasmic and nuclear
The incubation with secondary antibodies (UltraVision ONE HRP Polymer) took place during the second stage. We visualized the cell structural components using diaminobenzidine, which painted them in a brown color.
We calculated the share of different forms of immune cells and their ratio analyzing the histological and immunohistochemical study. The study was conducted in 10 fields of view at 400× magnification.
Mathematical calculations were done using Microsoft Excel 2010 with 12.0.5 Attestat option. We have found such indicators as chi-squared Pearson’s test, Student’s T-criterion, Pearson’s correlation coefficient (with statistical significance p < 0.05).
Interstitial - the leukocytes are located around the tumor as single scattered cells.
Trabecular – the immune cells form the layers or trabeculae.
Focal (nodular) – the leukocytes accumulate in focuses, sometimes with the formation of pseudo-follicles.
- 4.Diffuse - the immune cells occupy almost all the intercellular space giving the impression of metastasis in lymph nodes (Fig. 1).
Mixed – a combination of different forms of inflammatory infiltration.
In the stroma of the control group tissue the immune cells were also presented, because they are a part of the fibrous tissue of any organs, including the mammary gland. But they are located singly and very rare.
A clear relationship between the degree of malignancy of IDC and the type of inflammatory infiltrate has not been detected (p > 0.05). It was observed a tendency of infiltration increase in the case of the growth of polymorphism “cancerous” cells. This suggests a more pronounced reaction of macroorganism with the increase of cell’s anaplasia.
The molecular subtypes of breast cancer
The tumors with inflammatory infiltration
The tumors without inflammatory infiltration
We have established a direct correlation between the expression of ERα and PR (r = +0.78, p < 0.05) and indirect correlation between the receptors of steroid hormones and HER2/neo (r = −0.73, p < 0.05) in both groups of breast cancer. The combination of the steroid receptors absence and presence of HER2/neo with the presence of inflammatory infiltration in the tumor microenvironment have been established in our study. In most cases, it did not depend on the type of inflammatory infiltration.
Studying the expression of bcl-2 in cancer cells the investigation has showed that 40 % of tumors were bcl-2 positive. There was a combination of their presence with the steroid receptors expression in 90 % of cases. It was found that hsp90α in tumor cells were characterized by cytoplasmic and nuclear localization. Nearly 80 % cases of breast cancer were positive for Hsp90α expression, indicating their participation in tumor development. The correlation was established between the level of hsp90α expression by tumor epitheliocytes and the leukocyte infiltration in stromal tissue (p < 0.05). HER2/neo positive tumors in 100 % of cases were accompanied by the presence of heat shock proteins.
While studying the qualitative composition of the inflammatory infiltration it has been found that the immune cells were white blood cells of different nature. The lymphocytes dominated among them. We have established that the lymphocytes of T (CD3) and B (CD79α) cell lines were present among them. Such forms of the leukocytes as monocytes (S100) and various forms of granulocytes (MPO) were also present in the immune microenvironment of the tumor. B lymphocytes were present in 20 to 60 % of the total number of leukocytes. We found that the number of T lymphocytes has been approximately 25–70 % of the total number of leukocytes. The total number of T and B lymphocytes was 85–90 %. The number of granulocytes was 1–7 %, macrophages were up 15 %. The antigen presenting monocytes were observed in most cases with B lymphocytes. An important aspect of the research is the study of the ratio between different types of leukocytes. Our study showed that in the case of steroid-negative breast cancer the ratio В-lymphocytes:T-lymphocytes:granulocytes:antigen presenting monocytes was an average as follows 6:2,5:0,5:1. It means that the number of B lymphocytes was more than 60 % and T lymphocytes were near 25 %. There was found the indirect correlation between the presence of B lymphocytes and expression of steroid receptors (p < 0.05). The ratio of imunocytes in steroid-positive breast cancer was an average as follows 2:7:0,5:0,5.
Concerning PR, its quantity directly depends on the amount of ER. This indicates their simultaneous synthesis and dependence of PR from the presence and quantity of ER .
The progression of breast cancer depends on many factors, including the tumor microenvironment. The surrounding inflammatory infiltration in the list of prognostic factors is not the last place. We cannot exclude its effect on the expression of receptors. This is clearly seen in these types of breast cancer, such as medullary and inflammatory carcinoma, which are always accompanied by pronounced inflammatory infiltration in the microenvironment. They have the negative status of the receptors for steroid hormones in most cases.
In our opinion, there are several reasons for the appearance of immunocytes among the tumor cells. Therefore as a tumor is an immunologically foreign tissue, the macroorganism is constantly struggling with it. This is only possible on condition that different forms of leukocytes are involved in this process. On the other hand, the impact of exogenous factors that stimulate inflammation may also influence the course of carcinogenesis. For example an increased penetration of heavy metal salts into the body leads to their accumulation in tumor tissue. The activation of the immune system occurs by the stimulation of oxidase stress and increase of tissue calcification in which they take part.
Undoubtedly the inflammatory infiltration influences up the receptor expression, but as can be seen from our results it is not dependent on the type of infiltration. It depends on the qualitative composition of cellular microenvironment. The sequence of events is as follows. The macroorganism recognizing the tumor as a foreign substance starts primarily the cellular immunity. The more tumor cells are foreign the more this reaction is expressed. It consists of the activation of the antigen-specific cytotoxic T (CD3) lymphocytes by immunocompetent macrophages (S100), which can cause apoptosis of tumor cells. After that the apoptotic corpuscles are phagocytized by the segmented leukocytes (MPO). This process does not influence on the expression of ERα and PR.
We saw quite a different picture in the case of the involvement of the humoral immunity in the struggle against cancer. The antigen presenting cells recognize antigen presented by tumor cells and present it through IL-1 to Th2. Th2 through IL-3 activate B lymphocytes. The secretion of IL-1 is accompanied by the transition of NF-kB in the active form. NF-kB stimulates protein kinase B, also known as Akt, which inhibits the activity of forkhead box O3 (FOXO3A) . NF-kB influences on ER expression through stimulation of EZH2 (enhancer of zeste homolog 2) activity  and the activation of BLIMP-1 (PR domain zinc finger protein 1) . The reduction of the number of FOXO3A, increasing of the number of EZH2, Akt and BLIMP-1 inhibit ER transcription. As a consequence the expression of intranuclear receptors for estrogen is reduced. Based on this, we explain the absence of ER in our study when В lymphocytes predominate in the tumor microenvironment.
A correlation between the level of Hsp90α expression and the leukocyte infiltration in breast cancer stromal tissue shows the influence of the immune microenvironment on the presence of the heat shock proteins. His constant presence with HER2/neu positive breast cancer confirms his participation in tumor progression. Hsp90α stabilizes HER2/neu and modulates their effect . It stimulates the resistance of breast cancer to HER2/neu directed drugs . This may explain the fact why ERBB2 gene amplification is not always accompanied by the expression of HER2/neu, which may be linked to the lack of Hsp90α. This chaperone effects on ER and PR, on the one hand stabilizing their structure, on the other hand regulating activity of Akt and NF-kB [3, 22]. Hsp90 promotes the activation of anti-apoptotic protein kinases (bcl-2) and blocks APAF-1, the protein of internal apoptotic way, thereby bolstering the development of cell resistance to their programmed death . Based on this, increasing the number of Hsp90 in the conditions of oxidase stress and inflammation leads to the increase of tumor cell resistance and assists in the expression of prognostically unfavorable receptors. Hsp90 worsens the prognosis of breast cancer because it also modulates the synthesis of such proteins as p53, angiogenic factor HIF-1a, VEGF and others, which are aggressive factors in the cancer process .
Previous studies have shown that Bcl-2 was expressed almost exclusively in ER+ diseases (about 85 %) because BCL2 is an estrogen-responsive gene . The same results have been obtained in our studies in estrogen-positive breast cancer cases. It is believed that the presence of Bcl-2 receptors is a favorable prognostic factor . While Bcl-2 has emerged as an important prognostic marker in breast cancer, its precise role as a predictive marker or therapeutic target is not known . We believe that the presence of Bcl-2 protein is not an indicator of favorable course. This is one of the ways to improve the implementation of proliferative potential of cells through the ER. Inasmuch as a function of estrogen is the amplification of cell division, it can be implemented either through transcription of estrogen-dependent genes that are responsible for the separation or through activation of transcription estrogen-dependent genes that block apoptosis such as BCL-2. In our opinion the presence of Bcl-2 indicates a more aggressive course of breast cancer. Formerly it was considered as a prognostically favorable factor due to the presence in most cases the receptors of steroid hormones that are prognostically favorable markers of breast cancer.
Moreover the research has shown that therapeutic effect is enhanced in concurrent usage of the estrogen receptor inhibitors and BH3 mimetics, which have been developed to counteract antiapoptotic proteins such as Bcl-2 and Bcl-2-related proteins Bcl-XL and Bcl-W . There is also NF-кB-dependent way of activation synthesis anti-apoptotic members of the Bcl-2 family (Bcl-2, Bcl-XL and BFL1) [17, 31]. And again we must remember about inflammation, IL-1 and their effects on NF-kB synthesis, through which they support resistance of cancer cells in the struggle for survival. That is why we observed isolated cases Bcl-2 positive breast cancer (weakly intense reaction) in cases of ER absence.
Analyzing obtained data we can assert that immune microenvironment plays one of key roles in the progression of malignant process. This may explain those cases of breast cancer, when the cells with different phenotype of the receptor status can be found in one section. On the one hand, this means that the cells lose their ability to perceive signals from the macroorganism, on the other hand they adapt to new environment becoming more resistant. A similar situation occurs in metastases in the lymph nodes, where tumor cells are surrounded by B lymphocytes.
Immune system cells influence upon the course of cancer, but we haven’t found yet whether positive or negative. We consider that the immunocytes remove the influence of steroid hormones by blocking estrogen receptors as a factor of tumor initiation in the mammary gland. But in the future progress it begins to contribute to carcinogenesis progression.
The immune microenvironment through the activation of intracellular mediators blocks ERS genes transcription. This circumstance is possible due to the presence of B lymphocytes in an inflammatory infiltrate. It leads to the disappearance of estrogen receptors, and as a result to the disappearance of progesterone receptors. The inflammation provokes the accumulation of Hsp90 in a cell. It contributes to the stabilization of HER2/neu receptors and most proteins that promote tumor progression. The lack of estrogen receptors is a factor of locking estrogen-dependent gene BCL-2 transcription and as a consequence to the decrease of Bcl-2. All of the above stimulates the breast cancer progression by providing tumor more malignant opportunities.
We thank Zolotarova Vera who helped in the conduction of immunohistochemical reactions.
- Reeder JG, Vogel VG. Breast cancer prevention. Cancer Treat Res. 2008;141:149–64.PubMedView ArticleGoogle Scholar
- Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006;58(4):773–81.PubMedView ArticleGoogle Scholar
- Zagouri F, Sergentanis TN, Nonni A, Papadimitriou CA, Michalopoulos NV, Domeyer P, et al. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer. 2010;10:353–60.PubMed CentralPubMedView ArticleGoogle Scholar
- Gadkar-Sable S, Shah C, Rosario G, Sachdeva G, Puri C. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci. 2005;10:2118–30.PubMedView ArticleGoogle Scholar
- Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: Pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;25(23):3525–33.Google Scholar
- Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104(1):120–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012;107(5):864–73.PubMed CentralPubMedView ArticleGoogle Scholar
- Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009;69(21):8420–8.PubMedView ArticleGoogle Scholar
- Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des. 2009;15(17):1949–55.PubMedView ArticleGoogle Scholar
- Schmidt C. Immune system’s Toll-like receptors have good opportunity for cancer treatment. J Nat Cancer Inst. 2006;98:574–5.PubMedView ArticleGoogle Scholar
- Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2011;109(8):2796–801.PubMed CentralPubMedView ArticleGoogle Scholar
- Sas L, Lardon F, Vermeulen PB, Hauspy J, Dam PV, Pauwels P, et al. The interaction between ER and NF-κB in resistance to endocrine therapy. Breast Cancer Res. 2012;14:212–20.PubMed CentralPubMedView ArticleGoogle Scholar
- Belguise K, Sonenshein GE. PKCθ promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor α synthesis. J Clin Invest. 2007;117:4009–21.PubMed CentralPubMedGoogle Scholar
- Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Gelder ME, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011;125:387–94.PubMedView ArticleGoogle Scholar
- Wang X, Belguise K, O’Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, et al. RelB NF-κB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol. 2009;29:3832–4.PubMed CentralPubMedView ArticleGoogle Scholar
- Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation. Immunol Rev. 2005;203:21–37.PubMedView ArticleGoogle Scholar
- Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem. 2002;277(25):22781–8.PubMedView ArticleGoogle Scholar
- Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37:299–310.PubMed CentralPubMedView ArticleGoogle Scholar
- Martin LA, Dowsett M. BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer? 2013;24(1):7–9. doi: 10.1016/j.ccr.2013.06.006.
- Berezowska S, Novotny A, Bauer K, Feuchtinger A, Slotta-Huspenina J, Becker K, et al. Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas. PLoS One. 2013;8(7):37–45.View ArticleGoogle Scholar
- Lang SA, Klein D, Moser C, Gaumann A, Glockzin G. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007;6:1123–32.PubMedView ArticleGoogle Scholar
- Koga P, Xu W, Karpova TS. Hsp90 inhibition transiently activates Sic kinase ami promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A. 2006;103(30):11318–22.PubMed CentralPubMedView ArticleGoogle Scholar
- Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004;6(6):507–14.PubMedView ArticleGoogle Scholar
- Kregel KC. Ileal shock proteins: modifying factors in physiological stress responses and acquired Ihemiotolerance. J Appl Physiol. 2002;92(5):2177–86.PubMedView ArticleGoogle Scholar
- Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004;206:149–57.PubMedView ArticleGoogle Scholar
- Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrin. 2007;275(1–2):2–12.View ArticleGoogle Scholar
- Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668–75.PubMed CentralPubMedView ArticleGoogle Scholar
- Vaillant F, Merino D, Lee L, Breslin K, Pall B, Ritchie ME, et al. Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. Cancer Cell. 2013;24(1):120–9.PubMedView ArticleGoogle Scholar
- Lindeman GJ, Visvader JE. Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow? Breast Cancer Manage. 2013;2:1–4.View ArticleGoogle Scholar
- Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.PubMedView ArticleGoogle Scholar
- Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 2000;19(56):6627–31.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.